Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus ECF/X as first-line therapy in HER2/EGFR-positive gastric or esophagogastric junction adenocarcinoma
2009-011580-36Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of lapatinib in gastric adenocarcinoma, gastroesophageal adenocarcinoma and gastric cancer (GC), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival. Started Aug 2010; status: terminated.
02
Drugs
lapatinib
03
Conditions
gastric adenocarcinomagastroesophageal adenocarcinomagastric cancer (GC)
Beyond the preview
Go deeper on 2009-011580-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011580-36.